Related Experiment Video
Updated: Oct 21, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma
Roberto Iacovelli1, Maria Antonella Cannella1, Chiara Ciccarese1,2
1Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy.
Background:
The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium represents an unmissable event for oncologists who deal with renal cell carcinoma (RCC).
Aim And Results:
This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan).
Conclusions:
This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
More Related Videos
Related Concept Videos
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Targeted Cancer Therapies
There are several types of targeted therapies against...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management

